Literature DB >> 9359734

Pneumocystis carinii host origin defines the antibody specificity and protective response induced by immunization.

F Gigliotti1, A G Harmsen.   

Abstract

To determine how the known host species-specific antigenic variation of Pneumocystis carinii would affect immune recognition, mice were immunized with either mouse- or ferret-derived P. carinii, with subsequent analysis of the immune response and the ability of the mice to resist infection after immunosuppression and challenge. Immunization with mouse-derived P. carinii produced a strong immune response to mouse but not ferret P. carinii. These mice were completely protected from P. carinii pneumonia when challenged by intratracheal inoculation with mouse P. carinii. In contrast, immunization with ferret P. carinii produced a limited antibody response to mouse P. carinii and had no protective effect. These results show that P. carinii from different host species are immunologically distinct, and any possible use of immunotherapy for P. carinii pneumonia in humans must take into consideration these biologically significant antigenic differences in P. carinii of animal origin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359734     DOI: 10.1086/514128

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Elliott L Crow; Samir P Bhagwat; Terry W Wright
Journal:  Infect Immun       Date:  2006-08-28       Impact factor: 3.441

3.  Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers.

Authors:  S L Vargas; C A Ponce; F Gigliotti; A V Ulloa; S Prieto; M P Muñoz; W T Hughes
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

5.  Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.

Authors:  Beth A Garvy
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

6.  Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.

Authors:  Jesse Wells; Francis Gigliotti; Patricia J Simpson-Haidaris; Constantine G Haidaris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

9.  Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.

Authors:  Brenda L Tesini; Terry W Wright; Jane E Malone; Constantine G Haidaris; Martha Harber; Andrea J Sant; Jennifer L Nayak; Francis Gigliotti
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

10.  Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor.

Authors:  Chad Steele; Luis Marrero; Steve Swain; Allen G Harmsen; Mingquan Zheng; Gordon D Brown; Siamon Gordon; Judd E Shellito; Jay K Kolls
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.